Angelman Syndrome
Pipeline by Development Stage
Drug Modality Breakdown
Rare Diseases is a $21.9B market dominated by a single blockbuster (ELIQUIS), with moderate growth and high consolidation among top-tier pharma players.
Key Trends
- Market concentration: One product (ELIQUIS) represents 83% of market spending
- Complement inhibitors and enzyme replacement therapies gaining momentum
- Active pipeline with 1,790 trials, predominantly Phase 2-3 stage
Career Verdict
Yes, if you seek stability and commercial opportunity with major pharma; proceed cautiously if you want pipeline upside or innovation-driven roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 83% | LAUNCH | Stable | 15.0yr |
| 2 | XIFAXAN (rifaximin) | Bausch Health | $1.1B | 5% | LOE_APPROACHING | Declining | |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | PEAK | Stable | 10.2yr |
| 4 | TYVASO DPI (treprostinil) | United Therapeutics | $437M | 2% | PEAK | Stable | 15.7yr |
| 5 | STRENSIQ (asfotase alfa) | AstraZeneca | $259M | 1% | PEAK | Stable |
Drug Class Breakdown
Mature, patent-protected until 2041
Mixed—includes LOE-approaching products
Peak sales, LOE 2036
Stable, long patent protection
Emerging class, no LOE data available
Niche market, specialized patient populations
Career Outlook
StableThe rare disease market is stable but mature, with job growth concentrated in commercial and medical affairs rather than R&D innovation. Consolidation among top pharma (AstraZeneca, BMS, Amgen) limits opportunities for mid-tier companies, but specialist biotech firms show hiring momentum. Patent cliff risk for ELIQUIS (2041) will create restructuring opportunities and potential job flux in downstream years.
Breaking In
Target commercial or quality assurance roles at AstraZeneca, Capricor, or Amgen to build market knowledge; rare disease expertise is portable and valued across therapeutic areas.
For Experienced Professionals
Seek regulatory or medical affairs leadership roles where salary ceiling is highest ($243K-$257K); consider biotech firms like Insmed or Krystal for upside if pipeline approvals accelerate.
In-Demand Skills
Best For
Hiring Landscape
Rare disease hiring is concentrated in commercial roles (75 jobs at $215K avg) and medical affairs (16 jobs at $243K avg), reflecting a mature market's focus on market access and HCP engagement. Top hiring companies include AstraZeneca (38 jobs) and emerging biotech players like Capricor Therapeutics (30 jobs). Department salaries range from $114K-$257K, with regulatory affairs commanding premium compensation.
Top Hiring Companies
By Department
Commercial and regulatory roles offer strong salaries and growth; R&D hiring is minimal (10%), reflecting a consolidation and maturity phase in the market.
Competitive Landscape
12 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 20 trials with date data
Clinical Trials (21)
Total enrollment: 1,380 patients across 21 trials
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Long-term Extension of GTX-102 in Angelman Syndrome
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
A Study in Adults and Adolescents With Angelman Syndrome (STARS)
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
Angelman Syndrome (AS) Biomarker Study
Single Dose Pharmacokinetic (PK) Study
Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome
A Natural History Study of Angelman Syndrome
Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome
Angelman Syndrome Natural History Study-FAST UK
Angelman Syndrome Video Assessment (ASVA) Source Material Study
Nutritional Formulation for Angelman Syndrome
Italian Angelman Syndrome Registry
Related Jobs in Rare Diseases
Ingénieur Industrialisation Expérimenté - F/H
Director, Medical Writing
Senior Manager, International Accounting
LIMS System & Data Specialist II
Regional Business Director, Rare Disease - Northeast
Director, Quality Assurance & Quality Systems
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.